AbbVie Reports Third-Quarter 2025 Financial Results

AbbVie Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported a significant decrease in GAAP diluted EPS to $0.10, down 88.6% from the previous year, and adjusted diluted EPS of $1.86, a decrease of 38.0%. This decline includes an unfavorable impact of $1.50 per share related to acquired IPR&D and milestones expense. AbbVie's net revenues for the quarter were $15.776 billion, an increase of 9.1% on a reported basis. The company also raised its 2025 adjusted diluted EPS guidance range from $10.38 - $10.58 to $10.61 - $10.65, which includes an unfavorable impact of $2.05 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter. Additionally, AbbVie announced a 5.5% increase in its 2026 dividend, beginning with the dividend payable in February 2026.